IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with George Magrath, M.D., Chief Executive Officer of Lexitas Pharma. Dr. Magrath, who continues to practice medicine part time, spoke to IPO Edge Editor-in-Chief John Jannarone about investments in pharma and life sciences companies, how ophthalmic startups are different than other pharma startups and provided advice about funding an ophthalmic company. Watch the full recording below:
About Lexitas Pharma
We are a 100%-ophthalmics focused product development partner dedicated to helping life sciences companies bring new ophthalmic cures to patients. From study design through close-out, our extensive capabilities, deep ophthalmology expertise and close connections with ophthalmic KOLs make the Lexitas difference.
About George Magrath
George Magrath, M.D., is Chief Executive Officer of Lexitas Pharma Services. He is a trained ocular oncologist, balancing his role as CEO with treating patients with rare eye conditions at the Medical University of South Carolina. Dr. Magrath has both an extensive medical and business background. While learning his craft with an internship in general surgery, a residency in ophthalmology at the Medical University of South Carolina, and a fellowship in ocular oncology at Wills Eye Hospital in Philadelphia, he also branched out into the business world with an MBA from The Citadel and Masters in applied economics from Johns Hopkins University. His dual role gives him a unique, 360-degree insight into the opportunities and challenges for ophthalmic drug development and the clinical trials industry. He’s a widely recognized expert in ophthalmic clinical trials, having published 30 peer reviewed articles and 2 textbook chapters, more than 50 national meeting posters or presentations, and has been involved with more than 100 ophthalmic clinical trials.
Contact:
IPO-Edge.com
Editor@ipo-edge.com
